Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,369,511
  • Shares Outstanding, K 70,172
  • Annual Sales, $ 289,590 K
  • Annual Income, $ 66,860 K
  • 60-Month Beta 2.35
  • Price/Sales 21.76
  • Price/Cash Flow 69.25
  • Price/Book 6.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -1.16
  • Number of Estimates 8
  • High Estimate -0.87
  • Low Estimate -1.25
  • Prior Year 2.40
  • Growth Rate Est. (year over year) -148.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.53 +7.09%
on 07/31/20
96.98 -7.76%
on 08/06/20
-0.02 (-0.02%)
since 07/10/20
3-Month
54.50 +64.13%
on 05/14/20
97.82 -8.56%
on 07/08/20
+28.16 (+45.95%)
since 05/11/20
52-Week
32.30 +176.93%
on 03/16/20
97.82 -8.56%
on 07/08/20
+39.45 (+78.90%)
since 08/09/19

Most Recent Stories

More News
Excision BioTherapeutics Appoints Veteran Genome Editing Expert TJ Cradick, PhD as Chief Scientific Officer

Excision BioTherapeutics, a biotechnology company dedicated to curing viral infectious disease using CRISPR, today announced the appointment of TJ Cradick, PhD to the position of Chief Scientific Officer....

SGMO : 12.14 (-2.72%)
CRSP : 89.45 (-1.45%)
Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up

Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

BMRN : 116.83 (-1.20%)
MRNA : 68.97 (-4.22%)
VRTX : 261.86 (-2.56%)
CRSP : 89.45 (-1.45%)
CRISPR Technology Global Market Report 2020-30: Covid 19 Growth and Change

, /PRNewswire/ -- Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery Plc., Integrated...

CRSP : 89.45 (-1.45%)
EDIT : 34.19 (-3.72%)
CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team...

CRSP : 89.45 (-1.45%)
3 Healthcare Stocks Absurdly OVERVALUED Right Now

Acceleron Pharma (XLRN), Tandem Diabetes Care (TNDM), and CRISPR Therapeutics (CRSP) are three overvalued healthcare stocks investor should avoid for now. The coronavirus pandemic has wreaked havoc...

XLRN : 92.88 (-2.87%)
TNDM : 95.43 (-4.84%)
CRSP : 89.45 (-1.45%)
BMY : 63.13 (+2.12%)
VRTX : 261.86 (-2.56%)
Breakthrough Properties Executes Full-Building Lease With Leading Gene Editing Company for Next Generation Life Science Development in Boston's Seaport Neighborhood

, /PRNewswire/ -- Breakthrough Properties announced that leading gene editing company, CRISPR Therapeutics, has signed a 263,500-square-foot lease agreement for the development referred to as "The 105,"...

CRSP : 89.45 (-1.45%)
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -41.30% and -99.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?...

CRSP : 89.45 (-1.45%)
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results

-Dosing re-initiated in clinical trials of CTX001(TM) for patients with severe hemoglobinopathies-

CRSP : 89.45 (-1.45%)
What's in Store for CRISPR (CRSP) This Earnings Season?

CRISPR Therapeutics (CRSP) is developing its lead gene-editing candidate for thalassemia and sickle cell disease. The company is expected to provide an update on its progress on the earnings call.

INCY : 92.98 (-1.42%)
ARNA : 62.81 (-1.98%)
VRTX : 261.86 (-2.56%)
CRSP : 89.45 (-1.45%)
CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility

-State-of-the-art facility to be located in Framingham, Massachusetts-

CRSP : 89.45 (-1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CRSP with:

Business Summary

CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

See More

Key Turning Points

2nd Resistance Point 94.02
1st Resistance Point 91.73
Last Price 89.45
1st Support Level 87.36
2nd Support Level 85.28

See More

52-Week High 97.82
Last Price 89.45
Fibonacci 61.8% 72.79
Fibonacci 50% 65.06
Fibonacci 38.2% 57.33
52-Week Low 32.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar